Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Next Previous
X
Search
Trial Profile

A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Fosciclopirox (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors CicloMed

    • Most Recent Events

    • 18 Dec 2023 According to a Notable labs media release, results data from this study further corroborate and extend four independent PPMP validation trials in collaboration with leading medical centers.
    • 18 Dec 2023 Initial safety and efficacy results from this trial, presented in a Notable labs media release.
    • 14 Nov 2023 According to a Notable labs media release, Safety and efficacy data from the Phase 2a trial for Fosciclopirox, being co-developed with Ciclomed, in adult patients with relapsed/refractory AML are anticipated before year-end 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top